Rationale: Lung function and chronic obstructive pulmonary disease (COPD) are heritable traits. Genome-wide association studies (GWAS) have identified numerous pulmonary function and COPD loci, primarily in cohorts of European ancestry.
The Hispanic/Latino population is the largest and fastest-growing minority population in the United States, accounting for 17% of the U.S. population currently and an estimated 33% by 2060 (1) . The Hispanic/Latino population in the United States is genetically diverse, with a mixture of European, African, and Amerindian genetic ancestries (2) (3) (4) .
Chronic obstructive pulmonary disease (COPD), characterized by persistent airflow obstruction (5, 6) , is the third-leading cause of death in the United States (7) . The prevalence of COPD in some Hispanic groups is lower than in non-Hispanic white individuals and African Americans in the United States (8) (9) (10) . In the HCHS/SOL (Hispanic Community Health Study/ Study of Latinos), the largest and bestcharacterized cohort of Hispanics/Latinos in the United States, the prevalence of COPD varied substantially by Hispanic/ Latino heritage, with Puerto Ricans and Cubans having a much higher prevalence of COPD than other Hispanic/Latino groups (10) . This difference in HCHS/SOL was explained by smoking and asthma history; however, other investigators have noted that Hispanic ethnicity is inversely associated with COPD phenotypes compared with white individuals (11, 12) and have hypothesized that genetic differences may lower risk of COPD in some Hispanic groups (11, 13) .
Examination of genetic risk among nonEuropean populations may reveal novel variants that yield new pathways to treatments, such as PCSK9 (14) . We are aware of only two genome-wide association studies (GWAS) of lung function or COPD-related phenotypes that analyzed Hispanics separately (13, 15) . One identified a novel variant near MAN2B1 that was associated with percent emphysema on computed tomography (CT) imaging (15) , and the other identified two loci that approached genome-wide statistical significance for COPD (13) . This literature contrasts with that among persons of European ancestry, in whom GWAS have identified multiple loci in genes for lung function and COPD (16) (17) (18) (19) (20) (21) (22) (23) (24) (25) (26) (27) (28) (29) To improve our current understanding of the genetic architecture of lung function-related traits in Hispanics/Latinos, we performed a meta-analysis for FEV 1 , FEV 1 /FVC, airflow limitation, and COPD among six Hispanic/Latino groups in the HCHS/SOL cohort (10, 30) . Findings were replicated in European, Hispanic, and African populations. Some of the results have been previously reported in abstract form (31) .
Methods Study Sample
HCHS/SOL is a community-based cohort study of 16,415 self-identified Hispanic/Latino persons aged 18 to 74 years recruited from four U.S. communities. The study design, cohort recruitment (10, 30) , and baseline clinical examination (32) have been previously described. Institutional Review Boards at each field center approved study protocols, and written informed consent was obtained from all participants.
For genetic analyses, HCHS/SOL participants were classified in six genetic analysis groups: Central American, Cuban, Dominican, Mexican, Puerto Rican, and South American. The genetic ancestry structure of these groups, including principal components (PCs) plots for all individuals, has been previously reported (33) . Henceforward, we will refer to the six genetic analysis groups as Hispanic/Latino ancestry groups.
Exclusion criteria were lack of valid spirometric or genetic data, missing covariates, near-exclusive Asian ancestry, and participants who were not classified in the Hispanic/Latino ancestry groups. Details are provided in the online supplement.
Phenotypic and Outcome Measures
Spirometry was conducted in accordance with American Thoracic Society/European Respiratory Society guidelines (34) using a dry-rolling sealed spirometer, as previously described (10) . Participants with prebronchodilator FEV 1 /FVC ratios less than 70% or the lower limit of normal were selected for post-bronchodilator spirometry, the former defined by National Health and Nutrition Examination Survey reference equations (35) , because those from HCHS/SOL (36) were not available during data collection.
Airflow limitation was defined as a prebronchodilator FEV 1 /FVC ratio less than 70% and COPD as a postbronchodilator FEV 1 /FVC ratio less than 70% (5). Control subjects had normal lung function, defined as a prebronchodilator FEV 1 /FVC ratio greater than 70% and FVC greater than 80% predicted.
Genotyping, Quality Control, and Imputation
Consenting HCHS/SOL subjects were genotyped at Illumina on the HCHS/SOL custom 15041502 B3 array. We applied This article has an online supplement, which is accessible from this issue's table of contents at www.atsjournals.org.
ORIGINAL ARTICLE standard quality-assurance and qualitycontrol methods (37), as previously described (33) . Genome-wide imputation was performed with the full, cosmopolitan 1000 Genomes Project phase 1 reference panel (38); associations for novel loci were confirmed with 1000 Genome phase 3 imputation panel. Details are provided in the online supplement.
Statistical Analyses
See the online supplement for details.
Quantitative lung function analyses.
Analyses of FEV 1 and FEV 1 /FVC ratio used linear mixed models, stratified by Hispanic/Latino ancestry group, and adjusted for age, age squared, sex, height, height squared, study center, smoking status, pack-years, sampling weights, and the first five PCs, as fixed effects. We used random effects for genetic relatedness (kinship) and household and community (block unit) to account for environmental correlation. Results from each Hispanic/Latino ancestry group were then meta-analyzed using the MetaCor method (39) . Genome-wide significance threshold was defined as P , 5 3 10
28
, the Bonferroni adjustment for 1 million independent tests (40) . A priori, we planned additional meta-analyses stratified by never versus ever smoking.
Analyses for airflow limitation and COPD. We analyzed airflow limitation and COPD in pooled analyses implementing the GMMAT software (41) to fit a logistic mixed model adjusting for age, sex, study center, smoking status, pack-years, sampling weights, the first five PCs, and Hispanic/Latino ancestry groups, as fixed effects and with random effects for kinship and block unit. Participants younger than 45 years were excluded.
Admixture mapping and analyses.
Local ancestry estimates were previously inferred in the HCHS/SOL (42) . A genomewide admixture mapping scan was performed using a linear mixed model, as described above, testing European, African, and Amerindian ancestries at each available local ancestry interval (LAI). Statistical significance for admixture mapping was set at P , 5.68 3 10 25 on the basis of previous simulation results for HCHS/SOL (43) . After discovering a genome-wide significant LAI association (at the admixture mapping level), we identified a candidate variant and performed conditional admixture mapping analysis (44) .
Replication of lung function SNPs. We pursued replication of novel loci associated with FEV 1 and FEV 1 /FVC in populations with Hispanic (13, (45) (46) (47) (48) (49) , AfricanAmerican (45, 46) , and European representation (16) . We performed a lookup in each individual study and then metaanalyzed across studies. For airflow limitation and COPD, we performed regional replication in publically available GWAS results of airflow obstruction in participants of European ancestry (22) 
GWAS of Lung Function across All Hispanic/Latino Ancestry Groups
Across all Hispanic/Latino ancestry groups, seven signals achieved genome-wide statistical significance, of which two were novel for lung function ( Table 2 ). The lead novel SNP, rs4791658, in the locus associated with FEV 1 ( Figure 1A ). Effect size and P values for rs4791658 across all lung function and COPD-related traits are shown in Table E1 .
At a Glance Commentary
Scientific Knowledge on the Subject: Lung function and chronic obstructive pulmonary disease (COPD) are heritable traits. Prior genome-wide association studies (GWAS) of lung function have identified numerous genetic variants associated with COPD risk; however, much of the individual variance in lung function remains unexplained. Furthermore, most of these studies have been limited to participants of European ancestry. Including multiethnic populations in GWAS research may identify novel variants that contribute to the etiology of lung function.
What This Study Adds to the
Field: This study, the largest GWAS of lung function and COPD to exclusively include Hispanic/Latino participants, identified eight novel signals, of which three replicated in independent populations. A novel locus for FEV 1 (rs4791658; ZSWIM7) replicated in a cohort of European ancestry. A locus for FEV 1 /FVC (rs145174011; HAL), in a previously identified region for FEV 1 /FVC in individuals of European ancestry and for percent emphysema in a Hispanic population, remained independent in conditional analyses but did not replicate. Admixture mapping identified a novel region associated with Amerindian ancestry and FEV 1 , which included a candidate variant (rs4133185) in the AGMO gene that replicated. In addition, we identified a SNP (rs7709630) for COPD, which replicated in individuals of European ancestry. Several loci previously identified in European samples were also associated with lung function traits among Hispanic/Latino participants in the Hispanic Community Health Study/Study of Latinos at the genome-wide significance level. These results emphasize the importance of including admixed populations when performing genetic studies to identify variants that may contribute to the genetic etiology of pulmonary function and COPD.
The lead novel SNP, rs145174011, in the locus associated with FEV 1 /FVC ( Figure 1C ) was an intronic variant in the gene HAL on chromosome 12 (b = 4.86, P = 9.59 3 10 29 ). The SNP is rare, with an MAF that ranges from 0.001 to 0.008 across Hispanic/Latino ancestry groups ( Figure 1D ). The minor allele does not exhibit an outlier effect ( Figure E5 ). Sensitivity analysis using rank-normalized residuals is shown in the online supplement. This locus is near the gene CCDC38, which was previously identified for FEV 1 /FVC in individuals of European Ancestry (16) , and the gene SNRPF, which was previously identified for percent emphysema on CT imaging in racially/ethnically diverse participants (15) . In conditional analysis adjusting for rs1036429 (CCDC38) and rs7957346 (SNRPF) in HCHS/SOL, rs145174011 (HAL SNP) remained associated with FEV 1 /FVC (b = 4.92, P = 6.4 3 10 29 ), suggesting its association with FEV 1 /FVC is independent of previously identified variants. The findings for rs145174011 among ever and never smokers are concordant and trended toward significance (Table E1) . Regional association plots and forest plots of Definition of abbreviations: b (FEV 1 ) = per-allele change in FEV 1 (ml); b (FEV 1 /FVC) = per-allele change in FEV 1 /FVC %; Chr = chromosome; EAF = effect allele frequency; GEMIN5 = gem nuclear organelle-associated protein 5; GPR126 = G protein-coupled receptor 126; HAL = histidine ammonia-lyase; KCNE2 = potassium channel, voltage-gated subfamily E regulatory b subunit 2; KIF4B = kinesin family member 4B; KIF25 = kinesin family member 25; N = sample size used in testing the given variant; nearest gene = the nearest genes on each side of the intergenic marker; oevar = observed/expected variance; ZSWIM7 = zinc finger, SWIM-type containing 7.
Analyses were performed using data imputed to 1000 Genome phase 1 data and stratified by Hispanic/Latino ancestry group and were adjusted for age, age squared, sex, height, height squared, smoking status, pack-years, sampling weights, first five principal components, Hispanic/Latino ancestry groups, kinship, and block unit. Within-subgroup estimates were then meta-analyzed. Previously unreported associations are in bold. Retrospectively, association analyses using genetic data imputed to 1000 Genome phase 3 imputation panel were performed in novel loci. *oevar is provided by MACH software as a measure of imputation quality. †
Results for analyses using genetic data imputed to 1000 Genome phase 3 imputation panel. ‡ Genotyped SNP in locus.
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previously reported genome-wide significant associations for FEV 1 and FEV 1 /FVC meta-analyzed across all Hispanic/Latino ancestry groups are shown in Figure E6 .
Stratification by Smoking Status
In the meta-analysis across all Hispanic/Latino ancestry groups stratified by smoking status, we identified one novel locus among ever smokers for FEV 1 and one novel locus among never smokers for FEV 1 /FVC (Table 3 ). The lead variant in the locus associated with FEV 1 in ever smokers was an indel variant (P = 1.66 3 10 28 ) on chromosome 11. The top SNP, rs291231 (b = 57.28, P = 1.92 3 10 28 ), in this locus has an MAF that ranges from 0.28 to 0.42 across Hispanic/Latino ancestry groups. This SNP lies between the genes EED and CCDC81 (Figures 2A  and 2B ). The SNP-by-pack-years interaction trended toward significance (P-interaction = 0.06), and the genotype effect became greater at higher packyears ( Figure E7 ).
The top SNP (rs7228593) in the locus associated with FEV 1 /FVC in never smokers (b = 1.34, P = 3.47 3 10 28 ) is located between the genes SMIM21 and LOC339298 ( Figure 2C ) on chromosome 18. The findings in never smokers for airflow limitation (odds ratio, 0.46; P = 2.63 3 10 24 ) and COPD (odds ratio, 0.36; P = 0.005) were directionally concordant and trended toward significance (Table E1) . Its MAF varies significantly across different Hispanic/Latino ancestry groups ( Figure 2D) , with the highest in participants from the Dominican ancestry group (MAF = 0.16) and lowest in Mexican ancestry group (MAF = 0.02). Forest plots and regional association plot of remaining genome-wide significant associations for FEV 1 and FEV 1 /FVC stratified by smoking status are shown in Figure E8 .
GWAS of COPD
We identified two previously unreported SNPs for COPD (Table E2 and Figure E9 ). SNP rs7709630 is an intron in the PDZD2 gene on chromosome 5 (P = 1.56 3 10 28 , MAF = 0.11), and SNP rs2286351 is a noncoding transcript variant in CDRT15P1 Table E3 .
Admixture Mapping
Manhattan plots from admixture mapping analyses for FEV 1 and FEV 1 /FVC testing Amerindian, African, and European ancestry counts individually in LAIs are shown in Figures E10 and E11 . We identified one novel significant local ancestry association region of Amerindian ancestry for FEV 1 ( Figure E10A ) on chromosome 7 (b = 237.51, P = 2.86 3 10
26
). There were no significant associations in the European versus others or African versus others analyses.
We identified a candidate variant (rs4133185) within this novel LAI region (b = 231.44, P = 7.43 3 10 27 ; Table E4 and Figure 3 ) with considerable differences in ancestry-specific allele frequencies (Figure 4) . The lead SNP, rs4133185, in this candidate variant was an intron variant in the gene AGMO. The admixture mapping signal is less significant after conditional analyses adjusting for rs4133185 (Table E5 and Figures 4 and E12 ).
Replication
Characteristics of the participants in the replication cohorts are shown in Table E4 . Of the two novel loci identified for lung function, only the FEV 1 locus on chromosome 17 successfully replicated (replication P = 3.37 3 10 25 ; adjusted threshold for statistical significance was P , 9.2 3 10 24 ) but only in the SpiroMeta consortium look-up (n = 94,612) (16) . The candidate variant (rs4133185), identified through admixture mapping, associated with Amerindian ancestry and FEV 1 replicated in the UK Biobank (b = 28.3, P = 0.004). SNP rs291239, a genotyped SNP in the novel locus on chromosome 11 identified for FEV 1 among ever smokers, approached statistical significance for replication in the meta-analysis across all cohorts with admixed populations of African ancestry (replication P = 0.007); however, the direction of effect was discordant in the individual replication cohorts (Table E7) .
The novel SNP (rs7709630; PDZD2) associated with COPD regionally replicated in publically available results from the SpiroMeta-CHARGE (Cohorts for Heart and Aging Research in Genomic Epidemiology) GWAS meta-analysis of airflow obstruction among participants of European ancestry (22) . The smallest P value in the replication region was for rs409839 (P = 8.9 3 10 24 ), and the adjusted threshold for statistical significance was P , 4.2 3 10
23
. The other loci were not successfully replicated.
Generalization Analyses of Previously Identified Lung Function Loci
Using the false discovery rate-adjusted look-up threshold, several of the previously reported SNPs for FEV 1 , FEV 1 /FVC, and COPD identified in European populations were generalized to Hispanic/Latino populations (Tables E8-E10 and Figure  E13 ). See online supplement for details.
Discussion
In this GWAS of 11,822 Hispanic/Latino HCHS/SOL participants, we identified eight novel signals, of which three replicated in independent cohorts of European ancestry. Three novel signals were associated with lung function. A novel locus in ZSWIM7 (rs4791658) associated with FEV 1 replicated, and a rare variant in HAL (rs145174011) associated with FEV 1 /FVC did not replicate; it is in a previously identified region but remained significant in conditional analyses, suggesting an independent effect. Admixture mapping identified a novel LAI region, with a candidate variant in the AGMO gene (rs4133185), associated with Amerindian ancestry and FEV 1 , which replicated. In smoking-stratified analyses, a novel locus (rs291231) associated with FEV 1 among 4,595 ever smokers approached statistical significance for replication in cohorts with admixed populations of African ancestry, and a novel SNP for COPD in PDZD2 (rs7709630) regionally replicated in individuals of European ancestry. In addition, we confirmed loci previously identified in European samples (KCNE2 [16] and GPR126 [26] ) for FEV 1 /FVC in this Hispanic/Latino sample.
Several SNPs in ZSWIM7 were associated with FEV 1 at genome-wide significance and replicated in independent cohorts of European ancestry. ZSWIM7 mutations were associated with colorectal adenomatous polyposis (51) , and in a GWAS of SNP-by-smoking interaction, ORIGINAL ARTICLE ZSWIM7 neared significance for systolic blood pressure (52) . ZSWIM7 is a highly conserved eukaryotic regulator of homologous recombination and plays an important role in error-free DNA repair processes for DNA double-strand breaks (DSBs) (53) (54) (55) . Unrepaired DSBs trigger cell senescence, apoptosis, and proinflammatory responses, all of which are established mechanisms in the pathogenesis of COPD (56) (57) (58) . Oxidative stress and cigarette smoke cause DSBs (59, 60) , and DSBs have been implicated in the pathogenesis of COPD (60) . Furthermore, patients with COPD have a greater number of unrepaired DSBs, which are associated with a higher expression of markers for senescence, apoptosis, and proinflammatory phenotypes compared with asymptomatic smokers and nonsmokers (60) . In our study, the effect size of ZSWIM7 for FEV 1 was of greater magnitude among ever smokers, which is consistent with known effects of cigarette smoke causing DSBs. Thus, ZSWIM7, through its regulation of homologous recombination and role in error-free DNA repair processes for DSBs, is relevant to the pathogenesis of COPD. A rare variant in HAL (rs145174011) was associated with FEV 1 /FVC among all participants. The minor allele was associated with decreases in FEV 1 /FVC of 4.9% and 6.3% (all participants and ever smokers, respectively), and with decreases in FEV 1 of 100 ml and 173 ml (all participants and ever smokers, respectively). It is possible that this variant was not successfully replicated because of lack of power, given that it is a rare variant in African and Hispanic populations and is not polymorphic in European populations (61) .
The HAL SNP (rs145174011) is near two previously identified loci for pulmonary traits (CCDC38 and SNRPF). CCDC38 has been associated with FEV 1 /FVC in individuals of European ancestry (16) , and SNRPF has been associated with percent emphysema on CT imaging in racially/ethnically diverse participants in the MESA (Multi-Ethnic Study of Atherosclerosis) Lung Study (15) . In the MESA Lung Study, linkage disequilibrium (LD) between SNRPF and CCDC38 accounted for much of the effect seen in white individuals and less so in African Americans and Chinese; however, the observed effect of SNRF on percent emphysema on CT imaging in Hispanics appeared to be independent from CCDC38 (15). In our study, the association of SNP rs145174011 (HAL locus) with FEV 1 /FVC was maintained in analyses conditioning on previously reported loci. Collectively, these data suggest there are three independent loci associated with COPD-related phenotypes in this region.
Although the HAL locus contained numerous SNPs, they were all imputed rare variants and did not replicate; therefore, further investigation, such as whole-genome sequencing of this region and functional studies, is required to refine these loci, confirm association, and understand their biological implications for COPD.
The HAL gene encodes the enzyme histidine ammonia lyase (62, 63) -the first step in histidine catabolism (64) . Low levels of histidine have been associated with increased inflammation and oxidative stress (65, 66) , and decreased concentrations of histidine were associated with advanced COPD and emphysema (67) . Recently, whole-exome sequencing in African Americans identified three rare loss-offunction variants in HAL that were associated with increased histidine levels and were inversely related to coronary heart disease risk in African American and European American populations. Thus, a functional HAL variant may decrease histidine levels and increase susceptibility to COPD and emphysema through its effects on oxidative stress.
The region associated with Amerindian ancestry and FEV 1 on chromosome 7 contained a candidate variant (rs4133185) within the AGMO gene. This SNP, rs4133185, has large differences in ancestry-specific allele frequencies (z0.8 for Amerindian and <0.2 for European and African) and is associated with obstructive physiology, as measured by FEV 1 (P = 7.43 3 10 27 ). In the conditional analysis, rs4133185 explains part, but not all, of the admixture signal. SNP rs4133185 may not be the causal variant, and the presence of multiple SNPs within the LAI region may explain the residual signal. A prior report showed an association of AGMO with FVC in a multiethnic population (68) . Future whole-genome sequencing studies are needed for better fine mapping of this region.
The chromosome 11 locus (rs291231) associated with FEV 1 among ever smokers nominally replicated in the meta-analysis across all cohorts with admixed populations of African ancestry. However, the direction of effect was discordant in some replication cohorts. Different directions of associations may be due to different patterns of LD with the causal variant between populations. The minor allele in rs291231 might be protective in ever smokers, as demonstrated by a per-allele increase in FEV 1 of 57.28 ml.
The chromosome 18 locus associated with FEV 1 /FVC among never smokers contained multiple SNPs. The lead SNP In the COPD analysis, SNP rs7709630, a genotyped intron variant in PDZD2, was a single SNP association with COPD. This genomic region replicated for airflow obstruction in an independent population of European ancestry (22) , suggesting a true association. The CDRT15P1 locus only contained imputed SNPs and did not replicate, thus reducing the probability that this is a true association with COPD.
We hypothesize that novel loci did not replicate because of small sample size of the Hispanic/Latino replication cohorts along with differing environmental exposures, differing LD, and the complex racial admixture (2) that varies by different Hispanic/Latino ancestry groups. Furthermore, the novel locus for FEV 1 /FVC in HAL and the chromosome 18 locus for FEV 1 /FVC among never smokers have marked differences in MAF between race and ethnic populations, suggesting genetic diversity between races in these loci. The highest MAF for the lead SNPs in the HAL and in the chromosome 18 locus were observed in African populations (MAF = 0.005 and 0.38, respectively) compared with virtually no variability in European populations for these loci (MAF = 0) (61) . The lack of variance of these loci in European populations limits the ability to replicate these loci, as the vast majority of GWAS of lung function have been performed in studies of European ancestry. Evidence for replication of the novel locus on chromosome 11 for FEV 1 in ever smokers was stronger in the meta-analysis of cohorts with admixed populations that include African ancestry compared with the meta-analysis of all cohorts (P = 0.007 and P = 0.04, respectively), supporting the need for additional studies on admixed populations to identify possible ethnicity-or race-specific variants that may elucidate novel pathways in the pathogenesis of COPD.
The study has several potential limitations. This population-based cohort of diverse Hispanic/Latino participants is subject to population stratification. Multiple loci demonstrated varying MAF across Hispanic/Latino groups, highlighting the complex racial admixture of Hispanic/Latino populations and raising the possibility of residual population stratification. However, we adjusted our analysis for PCs, and our inflation factors ranged from 0.988 to 1.026, which indicates good control of population stratification with small inflation. The COPD analysis consisted of 363 and 5,253 participants with and without COPD (respectively), which is a relatively small sample size for a GWAS. We optimized COPD phenotype by limiting the analysis to age greater than or equal to 45 years and used post-bronchodilator spirometry measurements to define COPD.
In conclusion, we identified novel biologically plausible signals associated with clinically important pulmonary measures with evidence for replication in ZSWIM7, AGMO, and PDZD2; confirmed previous reports of association with FEV 1 /FVC in KCNE2 and GPR126; and established that loci previously identified in European populations are generalizable in Hispanic/Latino populations. There is a paucity of genetic studies for lung function that include underrepresented minority populations, such as Hispanic/Latino (2, 70) and African populations (14, 25, 71, 72) . Our findings emphasize the importance of including admixed and multiracial populations when performing genetic studies of complex diseases and have the potential to advance our understanding of genetic risks for lung disease affecting Hispanic/Latino populations. n Author disclosures are available with the text of this article at www.atsjournals.org.
